miRNA diagnostics

interpace diagnostics logoPARSIPPANY, N.J., Jan. 12, 2016 /PRNewswire/ — Interpace Diagnostics (NASDAQ: IDXG) announced today that Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), the world’s leading health care diagnostics company, will begin offering Interpace’s new ThyraMirTM microRNA classifier test.  Physicians will be able to order ThyraMir through LabCorp, in addition to Interpace’s ThyGenX® oncogene panel, which LabCorp already offers. These innovative assays provide enhanced options for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.

Studies show that the combination of the two molecular tests provides unprecedented high sensitivity and specificity, enabling physicians to either rule in or rule out malignancy in thyroid nodules initially deemed indeterminate by standard cytology. In addition to providing more precise diagnostic information, performing the tests together will in many cases eliminate the need for patients to undergo a second fine needle biopsy to collect the specimen typically needed for further tests.

“This agreement with LabCorp expands the reach of our molecular diagnostic tests for indeterminate thyroid nodules, and is a significant step in increasing access to the unmatched benefits of [click to continue…]


Upcoming Live Webinar and Q&A Session with Dr Brian D. Adams of Harvard Medical School and sponsorde by Abcam:

“MicroRNAs as biomarkers and therapeutic targets in triple negative breast cancer”

January 21, 2016 | 11:00am EST/ 8:00am PST

Register here

Triple negative breast cancer accounts for a disproportionate share of the total breast cancer morbidity because of its aggressive behavior, increased incidence in younger women, and lack of effective targeted therapies. miRNAs could serve as superior therapeutic agents for this breast cancer type.

This webinar will review:

  • miRNAs and noncoding RNA biology
  • Dysregulation of miRNAs associates with disease etiology
  • miRNAs as biomarkers
  • Techniques used to profile and study miRNA biology
  • miRNAs as therapeutic agents and/or targets

Can’t attend the live webinar? Don’t worry! Simply register today and receive the on-demand recording in your inbox within 24 hours of the live event.

About the Speaker:

Brian D. Adams, PhDBrian D. Adams is currently an Instructor at Harvard Medical School in the lab of Dr Frank Slack with over 9 years of experience in the fields of microRNA and cancer research. Brian completed his graduate studies at the University of Connecticut, where he was the first to identify that miRNAs are a crucial regulator of hormone-responsiveness in breast cancer patients. He further completed his postdoctoral studies at Yale, where he investigated how miRNAs can serve as chemo-sensitizers in the context of normal hematopoietic recovery and acute myeloid leukemia.

Incoming search terms for this article:


COLUMBUS, Ohio, and NEW YORK, Sept. 26, 2013 /PRNewswire/ — The Ohio State University today announced the signing of an exclusive world-wide agreement with Microlin Bio Inc., licensing a large portfolio of Ohio State’s groundbreaking cancer discoveries. The portfolio includes nearly 100 issued and pending microRNA patents that could lead to entirely new, more effective and more targeted ways to diagnose and treat prostate, ovarian, colon and lung cancers. Additionally, Microlin Bio Inc. has licensed a novel nucleic acid delivery technology to deliver these transformational therapies to cancer cells.

These technologies, years in the making, were developed by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) researcher Carlo Croce, M.D., The Ohio State University College of Pharmacy researcher Robert Lee, Ph.D., and collaborators from the National Cancer Institute with the National Institutes of Health.

Just over 10 years ago, Croce was the first in the world to link small cellular molecules called microRNA to cancer. MicroRNAs are now known to play a pivotal role in the growth and spread of many [click to continue…]


NEW YORK, Sept. 19, 2013 /PRNewswire/ — Exosome Diagnostics today announced it has entered into a collaboration agreement with Eli Lilly and Company (NYSE: LLY) for biomarker discovery and validation using Exosome Diagnostics proprietary EXO50 nucleic acid extraction kit.  Under the agreement, Lilly will gain early access to Exosome Diagnostics technology to help identify key gene mutations and expression levels in blood that may be correlated with drug response and disease recurrence.  Financial terms were not disclosed.

“Exosome Diagnostics technology may provide a unique opportunity to gain insight into the biology of complex conditions such as cancer and immune disorders,” said Andrew Schade, senior medical director, diagnostic and experimental pathology at Lilly. “Exosome technology enables biofluid molecular sampling and the ability to monitor disease progression in real time. As Lilly explores new ways to pursue patient tailoring, we’ll continue to work with partners to expand our capabilities.”

“Accessing high quality messenger and microRNA directly from frozen patient fluid samples offers a rapid, cost-effective route to identify and validate biomarkers, which may be correlated with drug response and disease recurrence,” said James McCullough, chief executive officer of Exosome Diagnostics. “Lilly has accumulated an [click to continue…]


Demonstrating Increased Demand for the Rosetta Cancer Origin Test

PRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Sep 10, 2013) – Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today reports financial results for the six months ended June 30, 2013.

Commercial highlights for the first half of 2013 and recent weeks include:

  • Enhanced awareness of, and demand generation for, the Rosetta Cancer Origin Test™ resulting in a four-fold increase in revenues compared with the same period a year ago
  • Expanded the U.S. commercial footprint from five sales territories to 12, and increased the direct sales force from four representatives to 10; brought sales professionals in house from contract sales organization
  • Received the final revised Local Coverage Determination for Biomarkers in Oncology from the designated Medicare Administrative Contractor for the Company’s microRNA-based diagnostic assays, which included [click to continue…]


Signature MicroRNA Expression Patterns Identified in Humans with 22q11.2 Deletion/DiGeorge Syndrome

February 26, 2013

Researchers at the University of Texas Southwestern Medical Center and Baylor Institute for Immunology Research have identified a novel expression signature in patients with DiGeorge Syndrome. DiGeorge Syndrome occurs because of a chromosomal deletion in 22q11.2, resulting in the hemizygous deletion of > 60 genes and 4 microRNAs. Peripheral blood taken from 31 DiGeorge Syndrome […]

Read the full article →

miRview® lung – Final Approval for Rosetta Genomics’ microRNA Diagnostic Allows Identification of Four Major Subtypes of Lung Cancer

November 6, 2012

New, Targeted Therapies Make Accurate Classification of Lung Cancer Increasingly Important PHILADELPHIA and REHOVOT, Israel, Nov. 6, 2012 /PRNewswire/ — Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic assays, announces that the New York State Department of Health has given the Company final approval for its miRview® lung assay following conditional […]

Read the full article →